Q-omics provides the consensus-scored MROH6 profile across patient tissues and cancer cell-line models. MROH6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MROH6 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, MROH6 RNA expression shows 15,640 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRC, COAD, and PAAD as cancer lineages where MROH6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MROH6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MROH6 survival associations across molecular data types. MROH6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MROH6 RNA expression–survival associations across cancer types. High MROH6 expression shows unfavorable associations in KIRC, ACC, LGG, UVM, UCS and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MROH6 RNA expression.
This table summarizes MROH6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MROH6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MROH6 shows higher tumor expression in COAD, THCA, LUAD, LIHC, KIRC and READ. The COAD box plot shows higher MROH6 RNA expression in tumor versus normal tissue (log2 FC = +2.305, t-test p < 0.001).
This table shows molecular features associated with MROH6 in patient tissues and cancer cell lines. In patient samples, MROH6 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MROH6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
